Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Huda Salman, MD, PhD
Indiana University
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida 33136
Miami, Florida, United States
Amer Beitinjaneh, MDRecruiting - Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana, United States
Huda Salman, MD, PhDRecruiting - Albert Einstein Health Network
The Bronx, New York, United States
R. Alejandro Sica, MDNot, yet, recruiting - the University of Texas Md Anderson Cancer Center
Houston, Texas, United States
Nicholas Short, MDRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 21 Feb 2024
- Primary completion
- 31 Dec 2028
- Completion
- 31 Dec 2043
- Last update posted
- 24 Jun 2026
- Registered enrollment
- 30
- Registry id
- NCT06071624
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.